Information was received from a healthcare provider (hcp) via a device manufacturer representative regarding a patient receiving fentanyl(17.504 mg/day, 25.0 mg/ml), marcaine(3.509 mg/day, 5.0 mg/ml), dilaudid (17.504 mg/day, 25.0 mg/ml) and ketamine(14.003 mg/day, 25.0 mg/ml) via an implantable infusion pump for the treatment of non-malignant pain.The old drug before the concentration change was fentanyl(17.504 mg/day, 25.0 mg/ml), marcaine(3.509 mg/day, 5.0 mg/ml), dilaudid (17.504 mg/day, 25.0 mg/ml) and ketamine(14.003 mg/day, 20.0 mg/ml).It was reported that the patient experienced labored breathing following a refill.A concentration change and bridge bolus was programmed by the nurse.It was noted that narcan was administered.The issue was resolved and patient status was alive with no injury at the time of the report.No further complication was reported.
|